Pancreatic cancer represents one of the leading causes of cancer-related death worldwide. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC), normothermic intraperitoneal chemotherapy (NIPEC), and pressurized intraperitoneal aerosol chemotherapy (PIPAC) has been proven with curative intent mainly for other tumors and there is a lack of consensus regarding possible benefits also in pancreatic cancer. The present systematic review and meta-analysis aim to provide an up-to-date overview of the effectiveness and safety of intraperitoneal treatments in the management of pancreatic cancer
With increasing awareness amongst physicians and improved radiological imaging techniques, the perit...
Background. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has been introduced as a novel ...
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is an emerging palliative treatment for pat...
Introduction and purpose: Pancreatic adenocarcinoma (PAC) is the third most common cancer of the gas...
Background and Aims. 5-year survival in patients with pancreatic cancer is poor. Surgical resection ...
\(\bf Background\) Patients suffering from peritoneal carcinomatosis of pancreatic adenocarcinoma w...
Recently, a novel method for chemotherapy administration inside the abdominal cavity gained wide at...
Background: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel intraperitoneal drug...
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a minimally invasive approach under inve...
INTRODUCTION: Systemic chemotherapy offers poor control over peritoneal disease, maybe as a conseque...
Aim: Gastric cancer is the cancer with the highest rate of peritoneal metastization and this type of...
Pancreatic cancer is rarely curable, and the overall survival rate at 5 years is under 4%. This stud...
In the world five-year overall survival of patients with pancreatic cancer is low, i.e. about 5–6%. ...
Background: Systemic chemotherapy for pancreatic adenocarcinoma (PDAC) and cholangiocarcinoma (CC) w...
Background: Peritoneal metastasis is a common and dismal evolution of several gastrointestinal (GI) ...
With increasing awareness amongst physicians and improved radiological imaging techniques, the perit...
Background. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has been introduced as a novel ...
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is an emerging palliative treatment for pat...
Introduction and purpose: Pancreatic adenocarcinoma (PAC) is the third most common cancer of the gas...
Background and Aims. 5-year survival in patients with pancreatic cancer is poor. Surgical resection ...
\(\bf Background\) Patients suffering from peritoneal carcinomatosis of pancreatic adenocarcinoma w...
Recently, a novel method for chemotherapy administration inside the abdominal cavity gained wide at...
Background: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel intraperitoneal drug...
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a minimally invasive approach under inve...
INTRODUCTION: Systemic chemotherapy offers poor control over peritoneal disease, maybe as a conseque...
Aim: Gastric cancer is the cancer with the highest rate of peritoneal metastization and this type of...
Pancreatic cancer is rarely curable, and the overall survival rate at 5 years is under 4%. This stud...
In the world five-year overall survival of patients with pancreatic cancer is low, i.e. about 5–6%. ...
Background: Systemic chemotherapy for pancreatic adenocarcinoma (PDAC) and cholangiocarcinoma (CC) w...
Background: Peritoneal metastasis is a common and dismal evolution of several gastrointestinal (GI) ...
With increasing awareness amongst physicians and improved radiological imaging techniques, the perit...
Background. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has been introduced as a novel ...
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is an emerging palliative treatment for pat...